Ovarian - Research Protocols

Ovarian

GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Stage Sex Cord-Stromal Tumors of the Ovary.
PI:  Abbie Fields, M.D

GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704864, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube and Peritoneal Primary Cancer.
PI:  Fouad Abbas, M.D.

CRAD001CUS242T: Phase II Single-Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum-Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer.
PI:  Kenneth Miller, M.D.

NRG GY003: Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
PI: Abbie Fields, M.D.
*****TEMPORARILY CLOSED*****

GOG 3005:  A Phase III Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
PI:  Abbie Fields, M.D.

For more information about ongoing clinical trials at the Alvin & Lois Lapidus Cancer Institute, please contact the oncology research team at 410-601-6120